Compare Mesoblast Limited (MESO) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $66.26 (market cap $7.43B). The key difference: Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is far larger — about 4.2× Mesoblast Limited's market cap, and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 1 Days on average.
| MESO | VIST | |
|---|---|---|
Market Cap | $1.75B | $7.43B |
Volume | 239,027 | 875,552 |
Sector | Health | Energy |
52-Week High | $20.96 | $79.25 |
52-Week Low | $13.19 | $35.02 |
Typical Hold Time | 15 Days | 1 Days |
Enterprise Value | $1.83B | $10.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
